Welcome to the international HTA database

Showing [16493 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2025	NIHR Health Services and Delivery Research programme	How lived experiences of illness trajectories, burdens of treatment, and social inequalities shape service user and caregiver participation in health and social care: a theory-informed qualitative evidence synthesis
2025	Agency for Care Effectiveness (ACE)	Asciminib for Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase after two or more tyrosine kinase inhibitors
2025	Agency for Care Effectiveness (ACE)	Atogepant and rimegepant for prophylaxis of migraine
2025	Agency for Care Effectiveness (ACE)	Epcoritamab for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy
2025	Agency for Care Effectiveness (ACE)	Finerenone for treating chronic kidney disease and albuminuria associated with type 2 diabetes
2025	Agency for Care Effectiveness (ACE)	Mavacamten for treating obstructive hypertrophic cardiomyopathy
2025	NIHR Health Services and Delivery Research programme	Enhancing referrals to child and adolescent mental health services: the EN-CAMHS mixed-methods study
2025	NIHR Health Services and Delivery Research programme	Barriers to and outcomes of unspecified kidney donation in the UK: BOUnD, a mixed-methods study
2025	NIHR Health Services and Delivery Research programme	After the disruptive innovation: How remote and digital services were embedded, blended and abandoned in UK general practice – longitudinal study
2025	NIHR Health Services and Delivery Research programme	The spiritual needs and care of children and young people with life-threatening or life-shortening conditions, and parents (SPARK): a mixed-method investigation
2025	NIHR Health Technology Assessment programme	Clinical and cost-effectiveness of detailed anomaly ultrasound screening in the first trimester: a mixed-methods study
2025	NIHR Health Technology Assessment programme	Pramipexole in addition to mood stabilisers for treatment-resistant bipolar depression: the PAX-BD randomised double-blind placebo-controlled trial
2025	NIHR Health Technology Assessment programme	Effects of pharmacological and non-pharmacological interventions for the management of sleep problems in people with fibromyalgia: a multi-methods evidence synthesis
2025	National Institute for Health and Care Excellence (NICE)	Omaveloxolone for treating Friedreich's ataxia in people 16 years and over (terminated appraisal). NICE technology appraisal guidance 1061
2025	National Institute for Health and Care Excellence (NICE)	Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma. NICE technology appraisal guidance 1059
2025	National Institute for Health and Care Excellence (NICE)	Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 1060
2025	National Institute for Health and Care Excellence (NICE)	Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor. NICE technology appraisal guidance 1062
2025	National Institute for Health and Care Excellence (NICE)	Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment. NICE technology appraisal guidance 1063
2025	National Institute for Health and Care Excellence (NICE)	Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency. NICE technology appraisal guidance 1064
2025	National Institute for Health and Care Excellence (NICE)	Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency. NICE technology appraisal guidance 1065
2025	National Institute for Health and Care Excellence (NICE)	Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy (terminated appraisal). NICE technology appraisal guidance 1068
2025	NIHR Health Services and Delivery Research programme	Emergency medical services streaming enabled evaluation in trauma: the SEE-IT Feasibility RCT
2025	NIHR Health Services and Delivery Research programme	Co-designing and testing the learn together guidance to support patient and family involvement in patient safety investigations: a mixed-methods study
2025	NIHR Health Technology Assessment programme	Behaviour change interventions to promote physical activity in people with intermittent claudication: the OPTIMA systematic review
2025	NIHR Health Technology Assessment programme	Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis: a systematic review and economic evaluation
2025	NIHR Health Technology Assessment programme	Sputum colour charts to guide antibiotic self-treatment of acute exacerbation of chronic obstructive pulmonary disease: the Colour-COPD RCT
2025	NIHR Health Services and Delivery Research programme	Implementing routine assessment of perinatal anxiety: case studies
2025	NIHR Health Services and Delivery Research programme	How to implement digital clinical consultations in UK maternity care: the ARM@DA Realist Review
2025	Health Information and Quality Authority (HIQA)	Evidence review of specialist cardiac services
2025	Agency for Care Effectiveness (ACE)	Deucravacitinib for moderate-to-severe chronic plaque psoriasis
2025	Agency for Care Effectiveness (ACE)	Durvalumab in combination with tremelimumab for treating unresectable hepatocellular carcinoma
2025	Agency for Care Effectiveness (ACE)	Glofitamab for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy
2025	Agency for Care Effectiveness (ACE)	Pembrolizumab for treating locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma
2025	Agency for Care Effectiveness (ACE)	Pembrolizumab for treating resectable Stage II, IIIA, or IIIB (T3-4N2) non-small-cell lung cancer
2025	Agency for Care Effectiveness (ACE)	Sacituzumab govitecan for unresectable locally advanced or metastatic HR-positive, HER2-negative breast cancer
2025	Agency for Care Effectiveness (ACE)	Triple therapy inhalers for treating asthma or chronic obstructive pulmonary disease
2025	Agency for Care Effectiveness (ACE)	Pneumococcal conjugate vaccines (15-valent and 20-valent) for the prevention of pneumococcal disease in adults
2025	NIHR Health Technology Assessment programme	Bisoprolol for patients with chronic obstructive pulmonary disease at high risk of exacerbation: the BICS RCT
2025	NIHR Health Technology Assessment programme	Effectiveness of biomarker-guided duration of antibiotic treatment in children hospitalised with confirmed or suspected bacterial infection: the BATCH RCT
2025	NIHR Health Technology Assessment programme	Establishing the best step-up treatments for children with uncontrolled asthma despite inhaled corticosteroids: the EINSTEIN systematic review, network meta-analysis and cost-effectiveness analysis using individual participant data
2025	NIHR Health Technology Assessment programme	Software with artificial intelligence-derived algorithms for detecting and analysing lung nodules in CT scans: systematic review and economic evaluation
2025	NIHR Health Technology Assessment programme	Rapid tests to inform triage and antibiotic prescribing decisions for adults presenting with suspected acute respiratory infection: a rapid evidence synthesis of clinical effectiveness and cost–utility studies
2025	National Institute for Health and Care Excellence (NICE)	Olipudase alfa for treating acid sphingomyelinase deficiency (Niemann–Pick disease) type AB and type B. NICE highly specialised technologies guidance 32
2025	National Institute for Health and Care Excellence (NICE)	Leniolisib for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over. NICE highly specialised technologies guidance 33
2025	Agency for Care Effectiveness (ACE)	Elastomeric infusion pumps for outpatient parenteral antimicrobial therapy
2025	Agency for Care Effectiveness (ACE)	Deep brain stimulators for treatment of Parkinson disease, dystonia or essential tremor
2025	Agency for Care Effectiveness (ACE)	Antibacterial envelope for implantable neurostimulator infection control
2025	NIHR Health Technology Assessment programme	Clinical and cost-effectiveness of lithium versus quetiapine augmentation for treatment-resistant depression in adults: LQD a pragmatic randomised controlled trial
2025	NIHR Health Technology Assessment programme	Technology-enabled CONTACT tracing in care homes in the COVID-19 pandemic: the CONTACT non-randomised mixed-methods feasibility study
2025	NIHR Health Technology Assessment programme	Anti-VEGF drugs compared with laser photocoagulation for the treatment of diabetic retinopathy: a systematic review and economic analysis
2025	Technology Assessment at SickKids (TASK)	A microcosting and cost consequence analysis from a randomized controlled trial comparing genome sequencing to exome sequencing for genetic diagnosis
2025	Agency for Care Effectiveness (ACE)	EchoGo Heart Failure to aid in the diagnosis of heart failure with preserved ejection fraction
2025	Agency for Care Effectiveness (ACE)	Fibresolve to aid in the diagnosis of idiopathic pulmonary fibrosis
2025	NIHR Health Technology Assessment programme	High-flow nasal cannula therapy versus continuous positive airway pressure for non-invasive respiratory support in paediatric critical care: the FIRST-ABC RCTs
2025	National Institute for Health and Care Excellence (NICE)	Balloon disimpaction of the baby's head at emergency caesarean during the second stage of labour. NICE interventional procedures guidance 800
2025	National Institute for Health and Care Excellence (NICE)	Pegylated liposomal irinotecan in combination for untreated metastatic pancreatic cancer (terminated appraisal). NICE technology appraisal guidance 1052
2025	National Institute for Health and Care Excellence (NICE)	Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A in people 2 years and over. NICE technology appraisal guidance 1051
2025	National Institute for Health and Care Excellence (NICE)	Ruxolitinib for treating acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and over. NICE technology appraisal guidance 1054
2025	National Institute for Health and Care Excellence (NICE)	Cladribine for treating active relapsing forms of multiple sclerosis. NICE technology appraisal guidance 1053
2025	National Institute for Health and Care Excellence (NICE)	Relugolix–estradiol–norethisterone for treating symptoms of endometriosis. NICE technology appraisal guidance 1057
2025	National Institute for Health and Care Excellence (NICE)	Molnupiravir for treating COVID-19. NICE technology appraisal guidance 1056
2025	National Institute for Health and Care Excellence (NICE)	Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy. NICE technology appraisal guidance 1055
2025	National Institute for Health and Care Excellence (NICE)	Tislelizumab in combination for untreated advanced non-small-cell lung cancer (terminated appraisal). NICE technology appraisal guidance 1058
2025	NIHR Health and Social Care Delivery Program	Opportunities and practices supporting responsive health care for forced migrants: lessons from transnational practice and a mixed-methods systematic review
2025	NIHR Health and Social Care Delivery Program	Approaches used to prevent and reduce the use of restrictive practices on adults with learning disabilities: a realist review
2025	NIHR Health Technology Assessment programme	A network approach to addressing the needs of patients with incurable head and neck cancer and their families
2025	NIHR Health and Social Care Delivery Program	The effectiveness and cost-effectiveness of the NHS Diabetes Prevention Programme (NHS-DPP): the DIPLOMA long-term multimethod assessment
2025	Penn Medicine Center for Evidence-based Practice (CEP)	Alpha-blocking medication before removal of indwelling urinary catheters
2025	NIHR Health and Social Care Delivery Program	Optimising neonatal services for very preterm births between 27+0 and 31+6 weeks gestation in England: the OPTI-PREM mixed-methods study
2025	NIHR Health and Social Care Delivery Program	Organising general practice for care homes: a multi-method study
2025	HTA South	[Ultraviolet light disinfection of flexible endoscopes without working channels: a systematic review and assessment of medical, economical, and organisational aspects]
2025	NIHR Health and Social Care Delivery Program	Exploring voluntary sector specialist services for victim-survivors of sexual violence in England: the PROSPER co-production study
2025	NIHR Health and Social Care Delivery Program	Direct oral penicillin challenge in secondary care with low-risk patients: the SPACE mixed-methods study with cost-effectiveness analysis
2025	NIHR Health Technology Assessment programme	Evaluation of prognostic models to improve prediction of metastasis in patients following potentially curative treatment for primary colorectal cancer: the PROSPECT trial
2025	NIHR Health Technology Assessment programme	Supporting self-management with an internet intervention for low back pain in primary care: a RCT (SupportBack 2)
2025	NIHR Health and Social Care Delivery Program	Formulating outputs from a mixed-methods study of access to general practice: a series of collaborative stakeholder workshops
2025	NIHR Health Technology Assessment programme	Lessons from the PROTECT-CH COVID-19 platform trial in care homes
2025	NIHR Health Technology Assessment programme	Stopping anticoagulation for isolated or incidental subsegmental pulmonary embolism: the challenges and lessons from the STOPAPE RCT
2025	NIHR Health Technology Assessment programme	Anti-VEGF drugs compared with laser photocoagulation for the treatment of proliferative diabetic retinopathy: a systematic review and individual participant data meta-analysis
2025	NIHR Health Technology Assessment programme	A personalised health intervention to maintain independence in older people with mild frailty: a process evaluation within the HomeHealth RCT
2025	NIHR Health Services and Delivery Research programme	Multiple Symptoms Study 3 – an extended-role general practitioner clinic for patients with persistent physical symptoms: a randomised controlled trial
2025	NIHR Health Services and Delivery Research programme	The impact of redeployment during COVID-19 on nurse well-being, performance and retention: a mixed-methods study (REDEPLOY)
2025	Health Technology Wales (HTW)	Use of advanced electrosurgical bipolar vessel sealing systems during hysterectomy compared to other methods for control of bleeding
2025	Health Technology Wales (HTW)	Permanent implant brachytherapy devices for the treatment of locally advanced, unresectable pancreatic cancer
2025	Health Information and Quality Authority (HIQA)	National guidelines for the budget impact analysis of health technologies in Ireland
2025	Health Information and Quality Authority (HIQA)	National guidelines for the economic evaluation of health technologies in Ireland
2025	National Institute for Health and Care Excellence (NICE)	Alcohol-mediated perivascular renal sympathetic denervation for resistant hypertension. NICE interventional procedures guidance 801
2025	National Institute for Health and Care Excellence (NICE)	12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites. NICE technology appraisal guidance 1045
2025	National Institute for Health and Care Excellence (NICE)	Atezolizumab for untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable (terminated appraisal). NICE technology appraisal guidance 1047
2025	National Institute for Health and Care Excellence (NICE)	Zolbetuximab with chemotherapy for untreated claudin-18.2-positive HER2-negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma. NICE technology appraisal guidance 1046
2025	National Institute for Health and Care Excellence (NICE)	Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over. NICE technology appraisal guidance 1050
2025	National Institute for Health and Care Excellence (NICE)	Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemia. NICE technology appraisal guidance 1049
2025	National Institute for Health and Care Excellence (NICE)	Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after first-line chemoimmunotherapy when a stem cell transplant is suitable. NICE technology appraisal guidance 1048
2025	NIHR Health Technology Assessment programme	A group psychological intervention for postnatal depression in British mothers of South Asian origin – the ROSHNI-2 RCT
2025	NIHR Health Technology Assessment programme	Recent research in myalgic encephalomyelitis/chronic fatigue syndrome: an evidence map
2025	NIHR Health Technology Assessment programme	Experiences of support to return to work after stroke: longitudinal case studies from RETAKE trial
2025	NIHR Health Technology Assessment programme	Gait Rehabilitation for Early rheumatoid Arthritis Trial (GREAT): lessons learnt from a mixed-methods feasibility study and internal pilot trial
2025	Austrian Institute for Health Technology Assessment (AIHTA)	Exagamglogene autotemcel (Exa-cel, Casgevy®)
2025	NIHR Health Technology Assessment programme	Benefits of aldosterone receptor antagonism in chronic kidney disease: the BARACK-D RCT
2025	Health Sciences Institute in Aragon (IACS)	Programme for the use of real world data in health technology assessment: using real-world data for health technology assessment